We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
50887 676 3 BTK
Emcee:  Biomaven Type:  Moderated
Biotech stocks are a close second only to internet stocks in how difficult they are to objectively value. This means that biotech stocks can be wildly under- or over-valued, which creates an opportunity for either profit or frustration for an investor that "knows better than market." To paraphrase the master: "Every now and again you should look at the stock price to see if the market is offering to do anything stupid."

This thread grew out of the "Munch-a-Biotech" thread, and is meant to discuss biotech stock valuation methods of all sorts, as well as particular stocks or sectors you may feel are under- or over-valued.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50887With the recent slide in biotech, I decided to publish the full list of biotechbmaz00147 hours ago
50886<Mkt is reacting to Trump and Pelosi maybe needing a deal on pricing imho.>Miljenko Zuanic112 AM
50885To each his own lol. This guy says election night 2016. I think he is nuts persoRobohogs-yesterday
50884SPX has gaps galore down to ~2700 or 6%. What would qualify as a "crash&qusemi_infinite -yesterday
50883We are OS here already. Valuation metrics? It all depends on politics tbh. Mkt iRobohogs-yesterday
50882<Bios are crashing a bit.> How much they need to crash to change metrics?Miljenko Zuanic-yesterday
50881Yes, MGL-3196 may be the best, but the price of MDGL shares compared to VKTX makArt Bechhoefer-yesterday
50880Do MGL and other NASH candidates have potential for other uses, given they lowerA.J. Mullen-yesterday
50879A source that is often wrong is screaming crash. Thing is he called yday for a tRobohogs-yesterday
50878I don't know. The drug companies, of course, want it to be chronic adminisatticus4paws-yesterday
50877One simple question: IF drug resolve NASH at 12/24/36...whatever weeks, do you sMiljenko Zuanic-yesterday
50876Looks likely IBB gap to close soon. XBI still has 10+% to go. Do the spx tea lsemi_infinite -yesterday
50875An interesting NASH article by a Madrigal investor: MGL-3196: Not Ideal, But Cutnsaf2yesterday
50874just a follow up on this one...for the record I think they will get approval, tholdirtybastard-yesterday
50873Besarab's erudite primer dates to 2016, and it was widely and valuably repriquidditch-Monday
50872Yes, that was the one. ArtArt Bechhoefer-Monday
50871A while back, someone on this thread posted a really good link to a seminar or DewDiligence_on_SI-Monday
50870Evidently the PJ analyst did not examine developmental data on roxadustat. A whArt Bechhoefer-Monday
50869Re: Indivior This will be a fascinating case to watch unfold. I suspect the Domr.optimistic-Sunday
50868With dose reduction Iloperidone lost effectiveness (relative to others in class)Miljenko Zuanic-Sunday
50867...drug development examples where the company was still trying to find a lowerDewDiligence_on_SI-Sunday
50866I know the big guys have prop trading desks, but didn't know PJ had one. I atticus4paws-Sunday
50865Sure. Not just Piper. All market makers.semi_infinite -Sunday
50864So Piper makes a market in FGEN, as well as attempts to time the stock, on the latticus4paws-Sunday
50863Piper Jaffray analyst Danielle Brill started FibroGen with a Neutral rating and JamesK-Sunday
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):